Panel A: Quantification of microvessel density count (MVD) based on CD31 staining were performed on WT mouse tumor tissues (200x magnification, scale = 100 μm). The graph shows the timepoints when tumors were collected to examine for MVD. The MVD was examined at 22 days after tumor implantation when tumor volume between the Scr and shGal-1 tumors showed the largest difference (panels A I and B I). At 22 days post-implantation, the MVD was significantly reduced in the shGal-1 tumor (n = 3, 34.0 ± 4.6 microvessels/mm2; tumor volume: 0.35 ± 0.15 cm3) when compared to the Scr tumors (n = 3, 62.0 ± 5.7 microvessels/mm2, tumor volume: 0.85 ± 0.25 cm3). The MVD of tumors at collected at >25 days after tumor implantation when tumor volume was comparable between the two groups was also examined (panels A II and B II). There was no difference in MVD between the Scr (n = 3, 40.1 ± 2.6 microvessels/mm2, tumor volume: 1.80 ± 0.25 cm3) and shGal-1 (n = 3, 40.9± 2.9 microvessels/mm2, tumor volume: 1.46 ± 0.42 cm3) tumors. Finally, the MVD of Scr tumors collected when the tumor volume (0.36 ± 0.08 cm3, < 22 days) was comparable to that of shGal-1 tumor at day 22 was examined (panels A III and B III). The MVD of the smaller Scr tumors (n = 3, 33.5 ± 1.6 microvessels/mm2) is simlar to the MVD of shGal-1 at day 22 post implantation (34.0 ± 4.6 microvessels/mm2). Panel C: quantification of MVD in Scr and shGal-1 tumors grown in B cell−/− and T-cell−/− mice showed no significant difference between the Scr and shGal-1 tumors. The average MVD for Scr in the B cell−/− host (n = 3, 43.3 ± 2.1 microvessels/mm2) and T-cell−/− host (n = 3, 22.8 ± 1.3 microvessels/mm2) did not differ from their respective shGal-1 tumors in the B cell−/− host (n = 3, 37.7 ± 3.7 microvessels/mm2) and T-cell−/− host (n = 3, 23.9 ± 1.0 microvessels/mm2).